SCHEMBL7014583

SCHEMBL7014583

CCOC(=O)c1ccn(C(=O)OC(C)(C)C)c1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA12 O43570 3/20 0.42
CA1 P00915 3/20 0.42
CA2 P00918 3/20 0.42
CA7 P43166 3/20 0.42
CA9 Q16790 3/20 0.42
CA14 Q9ULX7 3/20 0.42
ESR1 P03372 1/20 0.42
ESR2 Q92731 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.41
LMNA P02545 1/20 0.41
CYP1A2 P05177 1/20 0.41
CYP3A4 P08684 1/20 0.41
MAOA P21397 1/20 0.41
HPGD P15428 2/20 0.41
HTT P42858 2/20 0.41
ALDH1A1 P00352 3/20 0.40
CRHBP P24387 1/20 0.40
CRHR2 Q13324 1/20 0.40
GAA P10253 1/20 0.40
MAPT P10636 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31385878 0.85 CA12 (0.44) CA12CA1CA2CA7CA9
SCHEMBL7023132 0.83 NR1H2 (0.41) CA12CA1CA2CA7CA9
SCHEMBL19638080 0.80 GPR119 (0.38) ESR2ALDH1A1MAPTTDP1MEN1
SCHEMBL7824855 0.78 CRHBP (0.46) CA12CA1CA2CA7CA9
SCHEMBL18190298 0.78 L3MBTL1 (0.36) L3MBTL1CRHBPCRHR2MEN1KMT2A
SCHEMBL11911366 0.76 GPR119 (0.39) ESR2L3MBTL1LMNAALDH1A1MAPT
SCHEMBL21416268 0.76 CA12 (0.45) CA12CA1CA2CA7CA9
SCHEMBL18608207 0.74 CA1 (0.63) CA12CA1CA2CA7CA9
SCHEMBL31566784 0.73 L3MBTL1 (0.44) CA12CA1CA2CA7CA9
SCHEMBL12272048 0.73 TBXAS1 (0.40) CA12CA1CA2CA7CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3248980-B1 JAK INHIBITOR WUXI FORTUNE PHARMACEUTICAL CO LTD (CN) 2023-09-06 EP disclosed
CN-108349977-B JAK inhibitors 无锡福祈制药有限公司 2021-05-25 CN disclosed
US-10617690-B2 JAK inhibitor Wuxi Fortune Pharmaceutical Co., Ltd (CN) 2020-04-14 US disclosed
US-20170360794-A1 JAK INHIBITOR Wuxi Fortune Pharmaceutical Co., Ltd (CN) 2017-12-21 US disclosed
EP-3248980-A1 JAK INHIBITOR Wuxi Fortune Pharmaceutical Co., Ltd (CN) 2017-11-29 EP disclosed
CN-1468241-A Heterocyclic compounds as ligands of the gabaa receptor 2004-01-14 CN disclosed
EP-1325006-A2 HETEROCYCLIC COMPOUNDS AS LIGANDS OF THE GABA A? RECEPTOR NEUROGEN CORPORATION (US) 2003-07-09 EP disclosed
WO-2002012442-A2 HETEROCYCLIC COMPOUNDS AS LIGANDS OF THE GABAA RECEPTOR NEUROGEN CORPORATION (US) 2002-02-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170360794-A1 JAK INHIBITOR JAK2, JAK1, JAK3 CA12 4572/4885CA1 4783/4885CA2 3472/4885
US-10617690-B2 JAK inhibitor JAK2, JAK1, JAK3 CA12 4572/4885CA1 4783/4885CA2 3472/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.